Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer’s disease from AlzeCure Pharma for up to $1 billion biobucks.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer’s disease from AlzeCure Pharma for up to $1 billion biobucks.